Consolidated Financial Results
for the Nine Months Ended May 31, 2026
(Based on Japanese GAAP)

July 15, 2026

Company name:	MANI, INC.		
Stock exchange listing:	Tokyo		
Stock code:	7730 URL https://www.mani.co.jp/en/		
Representative:	Director, President and Representative Executive Officer	Masaya Watanabe	
Inquiries:	Managing Executive Officer, CFO	Takayuki Yamamoto	TEL +81-28-667-1811
Scheduled date to commence dividend payments:		-	
Preparation of supplementary material on financial results:		Yes	Scheduled to be disclosed on July 15, 2026
Holding of financial results meeting:		Yes	(For analysts)

(Amounts less than one million yen are rounded down)

1. Consolidated Financial Results for the Nine Months Ended May 31, 2026 (from September 1, 2025 to May 31, 2026)

(1) Consolidated Operating Results (cumulative)

(Percentages indicate year-on-year changes)

	Net Sales		Operating income		Ordinary income		Profit attributable to owners of parent	
Nine months ended	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
May 31, 2026	24,396	9.5	7,486	22.0	8,036	33.3	5,642	32.6
May 31, 2025	22,280	3.1	6,135	(5.6)	6,028	(15.4)	4,254	(16.3)

Notes Comprehensive income: For the nine months ended May 31, 2026 ¥7,620 million [83.8%]
For the nine months ended May 31, 2025 ¥4,146 million [(37.6%)]

	Earnings per share	Diluted earnings per share
Nine months ended	Yen	Yen
May 31, 2026	57.28	–
May 31, 2025	43.19	–

(2) Consolidated Financial Position

	Total assets	Net assets	Equity capital ratio
As of	Millions of yen	Millions of yen	%
May 31, 2026	62,474	57,242	91.6
August 31, 2025	57,987	53,561	92.4

Reference Equity
As of May 31, 2026 ¥57,242 million
As of August 31, 2025 ¥53,561 million

2. Cash Dividends

	Annual dividends per share				
	1Q-end	2Q-end	3Q-end	Year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended August 31, 2025	–	16.00	–	23.00	39.00
Fiscal year ending August 31, 2026	–	17.00	–		
Fiscal year ending August 31, 2026 (Forecast)				24.00	41.00

Notes Revisions to cash dividends most recently announced: None

3. Forecast of Consolidated Financial Results for the Fiscal Year Ending August 31, 2026 (from September 1, 2025 to August 31, 2026)

(Percentages indicate year-on-year changes)

	Net Sales		Operating income		Ordinary income		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	32,900	9.8	9,700	18.4	10,150	22.7	6,800	46.4	69.03

Notes Revisions to earnings forecasts most recently announced: Yes
*For further details, please refer to the disclosure “Notice Regarding Upward Revision of Full-Year Earnings Forecasts” disclosed on July 15, 2026.

※ Notes

(1) Significant changes in the scope of consolidation during the period: None

Newly included: –

Excluded: –

(2) Application of unique accounting methods in the preparation of quarterly consolidated financial statements: None

(3) Changes in accounting policies, changes in accounting estimates, and restatement

①Changes in accounting policies due to revisions to accounting standards and other regulations:	None
②Changes in accounting policies due to other reasons:	None
③Changes in accounting estimates:	None
④Restatement:	None

(4) Number of issued shares (common shares)

①Total number of issued shares at the end of the period (including treasury shares)

As of May 31, 2026	107,003,277 shares	As of August 31, 2025	107,003,277 shares

②Number of treasury shares at the end of the period

As of May 31, 2026	8,500,678 shares	As of August 31, 2025	8,500,674 shares

③Average number of shares during the period (cumulative from the beginning of the fiscal year)

Nine months ended May 31, 2026	98,502,602 shares	Nine months ended May 31, 2025	98,499,405 shares

※ Disclosure regarding quarterly review procedures

* Review of the Japanese-language originals of the attached consolidated quarterly financial statements by certified public accountants or an audit firm: Yes (voluntary)

* The English translation of the quarterly consolidated financial results will not receive a quarterly review by certified public accountants or an audit firm.

※ Proper use of earnings forecasts, and other special matters

* The forward-looking statements, including earnings forecasts, contained in these materials are based on information currently available to the Company and on certain assumptions deemed to be reasonable. Consequently, any statements herein do not constitute assurances regarding actual results by the Company. Actual business and other results may differ substantially due to various factors.

* This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

○ Attached Materials Index

1. Overview of Operating Results and Key Initiatives 2
   (1) Key Initiatives During the First Nine Months of the Fiscal Year 2
   (2) Explanation of the Operating Results for the First Nine Months of the Fiscal Year 3
   (3) Explanation of Financial Position for the First Nine Months of the Fiscal Year 4
   (4) Explanation of Future Forecast Information including Consolidated Business Results Forecasts 5
2. Quarterly Consolidated Financial Statements 6
   (1) Quarterly Consolidated Balance Sheet 6
   (2) Quarterly Consolidated Income Statements and Quarterly Consolidated Comprehensive Income Statements 8
      Quarterly Consolidated Income Statements
         For the nine months ended May 31, 2025 and May 31, 2026 8
      Quarterly Consolidated Comprehensive Income Statements
         For the nine months ended May 31, 2025 and May 31, 2026 9
   (3) Notes to Quarterly Consolidated Financial Statements 10
      (Notes on Premise of Going Concern) 10
      (Notes on Significant Changes in the Amount of Shareholders' Equity) 10
      (Notes on Quarterly Consolidated Statements of Cash Flows) 10
      (Notes on Segment Information, etc.) 10
      (Revenue Recognition) 11
      (Significant Subsequent Events of Going Concern) 11

1. Overview of Operating Results and Key Initiatives

(1) Key Initiatives During the First Nine Months of the Fiscal Year

MANI Group aims to contribute to the well-being of people around the world by providing our products worldwide, under our mission, "The Best Quality in the World, to the World." To achieve further growth, we launched a new medium-term management plan, "Medium-Term Management Plan 2029," starting from the fiscal year ending August 31, 2026. As we move toward becoming a centennial company, we are pursuing a robust growth strategy that reflects MANI's unique characteristics, such as our commitment to the "Best Quality in the World" and our "trade-off management" approach, to create corporate value.

(Details for Medium-Term Management Plan 2029: https://www.mani.co.jp/en/pdf/mg_plan_2029.pdf)

The main initiatives during the first nine months of the fiscal year ending August 31, 2026 are as follows:

Sales of MANI DIA-BURS Resumed in China; Recovery Exceeding Initial Targets

Regarding the "MANI DIA-BURS (classified as dental diamond burs)" that the Company manufactures and sells, the Company conducted a voluntary recall in March 2025 and substantially completed the recall by August.

Following approval from Chinese regulatory authorities on October 29, 2025, we officially resumed sales in November 2025. Driven by proactive sales and marketing activities conducted by our Chinese sales subsidiary, orders from many customers, including distributors and end-users, have resumed. As a result, sales recovery has progressed more rapidly than initially anticipated. During the first nine months of the fiscal year, recovery exceeded our original target of restoring sales to approximately 90% of the pre-recall level within two years. For the full fiscal year, sales are now expected to recover to approximately ¥2.1 billion, equivalent to approxiately 80% of the pre-recall level.

Given the strong sales momentum of dia-burs in China and the high likelihood that favorable sales trends will continue to exceed our plan, we have revised upward our consolidated earnings forecast for the fiscal year ending August 31, 2026.

(Millions of yen)

	Fiscal Year Ended August 31, 2024	Fiscal Year Ended August 31, 2025	Fiscal Year Ending August 31, 2026		
	Full-Year	Full-Year	First Quarter (From September to November)	Second Quarter (From December to February)	Third Quarter (From March to May)
	Results	Results	Results	Results	Results
Sales of China Dental (Index)	3,939 (100%)	2,467 (63%)	740 (60%)	1,121 (136%)	983 (94%)
Sales of dia-burs (Index)	2,553 (100%)	1,497 (59%)	298 (37%)	831 (156%)	579 (87%)

Index: Ratio to results of fiscal year ended August 31, 2024 for the relevant period

Progress in New Product Development

Under the Medium-Term Management Plan 2029, one of our key priorities is to significantly strengthen our R&D capabilities and accelerate the development of next-generation core products. From the fiscal year ending August 31, 2026, we launched several new product development projects and started developing products that have the potential to become future growth drivers for the Company.

The latest progress in product development is outlined below.

NiTi Rotary Files "JIZAI"	• Currently available in Japan, India, and Vietnam. − From the fiscal year ending August 31, 2027, we plan promotional activities in Japan for JIZAI-2, an enhanced version offering improved cutting performance. • Obtained Chinese regulatory approval ahead of schedule in May 2026. − Initial shipments to local distributors will begin in August 2026, with full commercial launch scheduled for September 2026. • Mass production at the Smart Factory is scheduled to begin in September 2026.
Vitreous Forceps	• Developed new products (27G and 25G models) with improved grip performance and launched them in Japan in April 2026. • Full-scale automated mass production at the Smart Factory is scheduled to begin in August 2028. • Future launches are planned in the United States, Europe, India, and China.

Progress at the Dental Restorative Materials Business at German Subsidiary MANI MEDICAL GERMANY GmbH

As part of efforts to turn around the performance of German subsidiary MANI MEDICAL GERMANY GmbH (hereinafter MMG), the Company decided to implement the following three reform initiatives, aiming to strengthen competitiveness and achieve sustainable growth in the dental business in Europe.

1. Selection and Focus on the OEM Business

   The Company is reviewing transaction terms with approximately 80 OEM customers and will focus on customers with whom it can enhance growth potential and profitability through co-creation.

2. Shift toward a Business Centered on Proprietary Brand Products

   MMG's standard products have been positioned as three proprietary brand products, which are "MANIFill (dental filling materials)," "MANIBond (dental bonding materials)," and "MANIShine (dental whitening materials)." From September 2025, sales of these three proprietary brand products have begun in the DACH region (Germany, Austria, and Switzerland). Leveraging the MANI Group's global sales network, these products are planned to be rolled out globally, including in Asia.

   Through the expansion of non-OEM products, the Company aims to secure profitability and standardize production and supply chain management.

3. Establishing MMG as a European Sales Hub for MANI Dental Products

   In addition to dental restorative materials, sales of dental products such as burs and files in Europe will be transferred to MMG, strengthening customer contact points in Europe and improving sales efficiency.

Share Acquisition in German Distributor iRIS EYE GmbH (Equity-Method Affiliate)

On December 22, 2025, we acquired 36.67% of the issued shares of iRIS EYE GmbH (hereinafter "iRIS"), our ophthalmic product sales distributor in Germany, making iRIS an equity-method affiliate of the MANI Group. To achieve further growth in the global surgical business centered on ophthalmic products, we position Europe as one of our key regions and will strengthen our sales functions with iRIS as the core.

Related press release: https://ssl4.eir-parts.net/doc/7730/announcement2/116520/00.pdf

(2) Explanation of the Operating Results for the First Nine Months of the Fiscal Year

Consolidated Financial Results: Revenue and Profit Increased Year on Year, Achieving a Record High Quarterly Net Sales

Net sales amounted to ¥24,396 million (up 9.5% year on year). This growth was driven by the continued depreciation of the yen, which boosted overseas sales, as well as strong growth in Dental products supported by the resumption of dia-bur sales in China and increased sales in India. In addition, steady growth in Eyeless Needle products, particularly in China and India, and strong sales of Surgical products in Europe, Japan, and North America contributed to overall revenue growth. Gross profit was ¥16,281 million (up 14.3% year on year), supported by revenue growth and an improvement in the cost of sales ratio following the resumption of dia-bur sales. Selling, general, and administrative expenses were ¥8,794 million (up 8.4% year on year). While the impact of performance-linked bonuses related to the results of the previous fiscal year was no longer present, personnel expenses at headquarters increased, along with ongoing investments associated with the launch of operations at our U.S. subsidiary, MANI MEDICAL AMERICA, INC., and organizational reforms at MMG. Despite these higher expenses, the increase in sales and gross profit more than offset the additional costs, resulting in a significant improvement in profitability. Operating income increased to ¥7,486 million (up 22.0% year on year). In addition to higher operating income, the Company recorded foreign exchange gains resulting from the depreciation of the Japanese yen. As a result, ordinary income increased to ¥8,036 million (up 33.3% year on year) and profit attributable to owners of the parent reached ¥5,642 million (up 32.6% year on year).

The following is an overview of financial results by segment. Segment sales figures are those from external customers.

(Millions of yen)

	Net sales		Segment income (Operating income)	
	Amount	Year on year	Amount	Year on year
Surgical products	7,392	6.0%	2,557	8.3%
Eyeless Needle products	8,900	6.8%	3,454	13.4%
Dental products	8,103	16.2%	1,473	102.4%
Consolidated total	24,396	9.5%	7,486	22.0%

(Surgical products)

Net sales were ¥7,392 million (up 6.0% year on year), and the segment income was ¥2,557 million (up 8.3% year on year). Sales growth was driven primarily by strong demand for ophthalmic knives used in cataract surgery, particularly in Europe, Japan, and North America. In China, however, sales remained weak due to changes in the market environment associated with healthcare policies and ongoing inventory adjustments by distributors. Segment income increased due to higher sales and an improvement in gross profit margins resulting from price revisions.

(Eyeless Needle products)

Net sales were ¥8,900 million (up 6.8% year on year), and the segment income was ¥3,454 million (up 13.4% year on year). The segment achieved both revenue and profit growth, supported by large orders received in Asia, particularly in China and India. In China, several customers of MANI's eyeless needle products have secured GPO contracts in multiple provinces, and shipments under these contracts are expected to begin in the fourth quarter of this fiscal year. In addition, global manufacturers have selected MANI's eyeless needle products for new projects in Thailand and India, reflecting customer recognition of the high quality and reliability of our products.

(Dental products)

Net sales were ¥8,103 million (up 16.2% year on year), and the segment income was ¥1,473 million (up 102.4% year on year). Revenue growth was driven primarily by the resumption of dia-bur sales in China, as well as strong sales performance in India. For MMG’s dental restorative materials business (OEM products), orders from key customers in North America remained stable, while sales to major customers in Europe remained weak. In addition, MMG is advancing the rollout of its proprietary MANI brand products in Europe as part of its medium- to long-term growth strategy. Segment income increased significantly from the previous year, benefiting from higher sales and improved gross profit margins following the resumption of dia-bur sales in China.

※Reference: Exchange rates

	Previous consolidated accounting period (Year ended August 31, 2025)				Current consolidated accounting period (Year ending August 31, 2026)			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
USD/JPY	149.03	151.57	149.77	148.91	151.50	153.73	155.42	—
EUR/JPY	161.99	161.25	161.51	163.62	176.38	179.85	181.52	—
CNY/JPY	20.88	21.00	20.71	20.63	21.28	21.82	22.28	—
INR/JPY	1.77	1.78	1.76	1.74	1.71	1.72	1.71	—

(3) Explanation of Financial Position for the First Nine Months of the Fiscal Year

(Millions of yen)

	As of August 31, 2025	As of May 31, 2026	Change
Total assets	57,987	62,474	4,486
Current assets	29,978	34,367	4,389
Non-current assets	28,009	28,106	97
Liabilities	4,425	5,232	806
Net assets	53,561	57,242	3,680

Total assets as of the end of the first nine months (May 31, 2026) increased by ¥4,486 million from the end of the previous fiscal year to ¥62,474 million. This was mainly due to a ¥4,389 million increase in current assets, reflecting a ¥5,336 million increase in cash and deposits, partially offset by a ¥1,080 million decrease in other current assets, primarily due to consumption tax refunds. Non-current assets increased by ¥97 million, mainly due to an increase in investment securities and other investments.

Total liabilities as of the end of the first nine months (May 31, 2026) increased by ¥806 million from the end of the previous fiscal year to ¥5,232 million. This was primarily attributable to a ¥781 million increase in current liabilities, driven by higher accrued expenses and income taxes payable.

Total net assets as of the end of the first nine months (May 31, 2026) increased by ¥3,680 million from the end of the previous fiscal year to ¥57,242 million. This was mainly due to an increase in retained earnings resulting from the recording of profit attributable to owners of the parent of ¥5,642 million, as well as a ¥1,975 million increase in foreign currency translation adjustments resulting from the depreciation of the yen. These factors were partially offset by the payment of dividends of ¥3,940 million.

(4) Explanation of Future Forecast Information including Consolidated Business Results Forecasts

In light of the strong business performance achieved through the first nine months of the fiscal year ending August 31, 2026, the Company has revised upward its full-year consolidated earnings forecast originally announced in the “Consolidated Financial Results for the Fiscal Year Ended August 31, 2025" on October 8, 2025.

For further details, please refer to the disclosure “Notice Regarding Upward Revision of Full-Year Earnings Forecasts” disclosed on July 15, 2026.

(Millions of yen)

	Net Sales	Operating income	Ordinary income	Profit attributable to owners of parent
Previous Forecasts (A)	32,800	9,200	8,950	6,450
Revised Forecasts (B)	32,900	9,700	10,150	6,800
Changes (B-A)	100	500	1,200	350
Changes (%)	0.3%	5.4%	13.4%	5.4%
Results of FY2025 (Reference)	29,968	8,193	8,271	4,643

2. Quarterly Consolidated Financial Statements

(1) Quarterly Consolidated Balance Sheet

(Millions of yen)

	As of August 31, 2025	As of May 31, 2026
Assets		
Current assets		
Cash and deposits	18,424	23,761
Notes receivable - trade	122	130
Accounts receivable - trade	2,851	2,946
Securities	310	5
Merchandise and finished goods	744	943
Work in process	3,147	3,193
Raw materials and supplies	2,446	2,535
Other	1,935	855
Allowance for doubtful accounts	(3)	(3)
Total current assets	29,978	34,367
Non-current assets		
Property, plant and equipment		
Buildings and structures, net	13,382	13,383
Machinery, equipment and vehicles, net	4,136	4,021
Land	4,432	4,477
Construction in progress	3,044	2,881
Other, net	761	753
Total property, plant and equipment	25,758	25,518
Intangible assets		
Software	557	430
Other	785	816
Total intangible assets	1,342	1,246
Investments and other assets		
Investment securities	63	303
Deferred tax assets	455	444
Insurance funds	248	232
Lease receivables	-	183
Other	141	177
Allowance for doubtful accounts	-	(0)
Total investments and other assets	908	1,341
Total non-current assets	28,009	28,106
Total assets	57,987	62,474

(Millions of yen)

	As of August 31, 2025	As of May 31, 2026
Liabilities		
Current liabilities		
Accounts payable - trade	250	210
Accounts payable - other	582	572
Lease liabilities	49	34
Income taxes payable	1,089	1,189
Provision for bonuses	423	372
Other	1,097	1,896
Total current liabilities	3,494	4,275
Non-current liabilities		
Lease liabilities	27	22
Retirement benefit liability	612	607
Asset retirement obligations	248	278
Other	43	47
Total non-current liabilities	931	956
Total liabilities	4,425	5,232
Net assets		
Shareholders' equity		
Share capital	1,087	1,087
Capital surplus	1,160	1,160
Retained earnings	48,925	50,627
Treasury shares	(3,118)	(3,118)
Total shareholders' equity	48,054	49,756
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	2	0
Foreign currency translation adjustment	5,481	7,457
Remeasurements of defined benefit plans	23	28
Total accumulated other comprehensive income	5,507	7,485
Total net assets	53,561	57,242
Total liabilities and net assets	57,987	62,474

(2) Quarterly Consolidated Income Statements and Quarterly Consolidated Comprehensive Income Statements

(Quarterly Consolidated Income Statements)

(Millions of yen)

	Nine months ended May 31, 2025	Nine months ended May 31, 2026
Net sales	22,280	24,396
Cost of sales	8,031	8,115
Gross profit	14,249	16,281
Selling, general and administrative expenses	8,113	8,794
Operating profit	6,135	7,486
Non-operating income		
Interest income	136	187
Gain on investments in investment partnerships	5	—
Share of profit of entities accounted for using equity method	—	10
Foreign exchange gains	—	659
Other	69	110
Total non-operating income	211	968
Non-operating expenses		
Interest expenses	2	1
Foreign exchange losses	114	—
Unoperated land-related costs	190	394
Other	10	21
Total non-operating expenses	318	418
Ordinary profit	6,028	8,036
Extraordinary income		
Surrender value of insurance policies	—	16
Gain on sale of non-current assets	12	3
Total extraordinary income	12	20
Extraordinary losses		
Loss on sale of non-current assets	0	—
Loss on retirement of non-current assets	13	0
Other	3	—
Total extraordinary losses	17	0
Profit before income taxes	6,023	8,055
Income taxes - current	1,612	2,402
Income taxes - deferred	156	10
Total income taxes	1,769	2,413
Profit	4,254	5,642
Profit attributable to owners of parent	4,254	5,642

(Quarterly Consolidated Comprehensive Income Statements)

(Millions of yen)

	Nine months ended May 31, 2025	Nine months ended May 31, 2026
Profit	4,254	5,642
Other comprehensive income		
Valuation difference on available-for-sale securities	(4)	(1)
Foreign currency translation adjustment	(108)	1,975
Remeasurements of defined benefit plans, net of tax	4	4
Total other comprehensive income	(107)	1,978
Comprehensive income	4,146	7,620
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	4,146	7,620

(3) Notes to Quarterly Consolidated Financial Statements

(Notes on Premise of Going Concern)

Not applicable.

(Notes on Significant Changes in the Amount of Shareholders' Equity)

Not applicable.

(Notes on Quarterly Consolidated Statements of Cash Flows)

The quarterly consolidated statement of cash flows for the first nine months of the fiscal year ending August 31, 2026 has not been prepared. Depreciation and amortization (including amortization of intangible assets) for the first nine months are as follows.

	Nine months ended May 31, 2025	Nine months ended May 31, 2026
Depreciation and amortization	¥1,832 million	¥1,825 million

(Notes on Segment Information, etc.)

[Segment Information]

I For the nine months ended May 31, 2025 (from September 1, 2024 to May 31, 2025)

1. Information on sales and income or loss by reportable segment

(Millions of yen)

	Reportable segments			Total	Adjustments	Amount on the consolidated financial statements (Notes)
	Surgical products	Eyeless Needle products	Dental products			
Net sales						
Net sales to external customers	6,976	8,332	6,970	22,280	—	22,280
Transactions with other segments	—	0	—	0	(0)	—
Total	6,976	8,333	6,970	22,281	(0)	22,280
Segment income	2,362	3,045	728	6,135	—	6,135

Notes Segment income is adjusted with operating income in the quarterly consolidated income statements.

II For the nine months ended May 31, 2026 (from September 1, 2025 to May 31, 2026)

1. Information on sales and income or loss by reportable segment

(Millions of yen)

	Reportable segments			Total	Adjustments	Amount on the consolidated financial statements (Notes)
	Surgical products	Eyeless Needle products	Dental products			
Net sales						
Net sales to external customers	7,392	8,900	8,103	24,396	—	24,396
Transactions with other segments	—	0	—	0	(0)	—
Total	7,392	8,901	8,103	24,397	(0)	24,396
Segment income	2,557	3,454	1,473	7,486	—	7,486

Notes Segment income is adjusted with operating income in the quarterly consolidated income statements.

(Revenue Recognition)

Breakdown information of revenue from contracts with customers

For the nine months ended May 31, 2025 (from September 1, 2024 to May 31, 2025)

Breakdown of revenue by region

(Millions of yen)

	Reportable segments			Total
	Surgical products	Eyeless Needle products	Dental products	
Japan	1,961	702	770	3,435
Asia	1,980	4,012	3,981	9,974
Europe	1,934	1,272	1,161	4,367
North America	399	1,199	499	2,098
Others	699	1,146	557	2,403
Revenue from contracts with customers	6,976	8,332	6,970	22,280
Other income	—	—	—	—
Net sales to external customers	6,976	8,332	6,970	22,280

For the nine months ended May 31, 2026 (from September 1, 2025 to May 31, 2026)

Breakdown of revenue by region

(Millions of yen)

	Reportable segments			Total
	Surgical products	Eyeless Needle products	Dental products	
Japan	2,157	740	807	3,706
Asia	1,802	4,676	5,151	11,630
Europe	2,214	1,343	1,162	4,720
North America	590	1,042	608	2,241
Others	627	1,097	373	2,097
Revenue from contracts with customers	7,392	8,900	8,103	24,396
Other income	—	—	—	—
Net sales to external customers	7,392	8,900	8,103	24,396

(Significant Subsequent Events of Going Concern)

Not applicable.